Idiopathic Pulmonary Fibrosis (IPF) has an estimated prevalence of 13 to 20 per 100,000 people worldwide* and is a condition ...Read more >
Lupuzor™ is an in-development treatment for Lupus, a chronic inflammatory disease thought to affect around 5 million people worldwide. Having ...Read more >
Simbec-Orion recently helped a biotech sponsor demonstrate the safety and tolerability of a new trial treatment for idiopathic pulmonary fibrosis ...Read more >
If you think we could be right for you, get in touch.